Evidence map›Paper›PMID 22735770›Full record

ReviewNeuropharmacology2013

Cognitive enhancement as a treatment for drug addictions.

Mehmet Sofuoglu, Elise E DeVito, Andrew J Waters, Kathleen M Carroll

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuropharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 152 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
152citing papers in PubMed, 6 pooled it
16.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

152 citing papers in PubMed, 6 syntheses or guidelines pooled it, 296 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. A quantitative review of cognitive functioning in homeless adults.The Journal of nervous and mental disease · 2015
    Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Modified cognitive behavioral therapy (M-CBT) for cocaine dependence: Development of treatment for cognitively impaired users and results from a Stage 1 trial.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2018
    Trial
  18. Trial
  19. Trial
  20. Functional neural changes following behavioral therapies and disulfiram for cocaine dependence.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2017
    Trial

92 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Mehmet SofuogluYale University, School of Medicine, Department of Psychiatry, VA Connecticut Healthcare System, 950 Campbell Ave., Bldg. 36/116A4, West Haven, CT 06516, USA. mehmet.sofuoglu@yale.edu
Elise E DeVito
Andrew J Waters
Kathleen M Carroll
Yale University · USUniformed Services University of the Health Sciences · USVA Connecticut Healthcare System · US

Funding

TSF to enhance treatment of cocaine dependenceP50DA009241 · NIDA · YALE UNIVERSITY · PI CARROLL, KATHLEEN M. · 1994 to 2018
$40.5M
Yale BIRCWH Scholar Program on Women's Health and Addictive BehaviorsK12DA031050 · NIDA · YALE UNIVERSITY · PI MAZURE, CAROLYN M. · 2010 to 2014
$2.5M
Human Laboratory Studies for Stimulant AddictionK02DA021304 · NIDA · YALE UNIVERSITY · PI SOFUOGLU, MEHMET · 2008 to 2011
$460k
NIDA NIH HHS K02 DA021304NIDA NIH HHS K02-DA-021304NIDA NIH HHS K12 DA031050NIDA NIH HHS K12-DA-031050NIDA NIH HHS P50 DA009241NIDA NIH HHS P50 DA09241
6 · The paper itself

Abstract

Drug addiction continues to be an important public health problem, with an estimated 22.6 million current illicit drug users in the United States alone. For many addictions, including cocaine, methamphetamine, and marijuana addiction, there are no approved pharmacological treatments. Behavioral treatments are effective but effects vary widely across individuals. Treatments that are effective across multiple addictions are greatly needed, and accumulating evidence suggests that one such approach may be pharmacological or behavioral interventions that enhance executive inhibitory control in addicts. Current evidence indicates that most forms of chronic drug use may be associated with significant cognitive impairments, especially in attention, working memory, and response inhibition functions. In some studies, these impairments predict poor treatment retention and outcome. A number of cognitive enhancing agents, including galantamine, modafinil, atomoxetine, methylphenidate, and guanfacine, have shown promising findings in human studies. Specific behavioral interventions, including cognitive remediation, also show promise. However, whether improvement of selective cognitive functions reduces drug use behavior remains to be determined. Cognitive enhancement to improve treatment outcomes is a novel strategy worthy of future research, as are related questions such as whether these approaches may be broadly beneficial to most addicts or best reserved for substance users with specific demonstrated cognitive impairments. This article is part of a Special Issue entitled 'Cognitive Enhancers'.

Indexed as

AnimalsBehavior TherapyCognitionCognition DisordersCombined Modality TherapyExecutive FunctionHumansNootropic AgentsSubstance-Related DisordersNootropic Agents

Identifiers

PMID22735770
PMCPMC3445733
OpenAlexW2055622849

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.